Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - What's Next?

Key Points

• IOVA shares plunged: The stock opened at $10.70 versus a prior close of $14.81 and last traded near $10.07 on heavy volume.
• Clinical data supported future expansion: Iovance reported a 24.6% response rate in the IOV-LUN-202 lung cancer trial, with higher rates in biomarker-selected groups, and plans to begin enrolling the POSITILITY study in November 2026.
• Outlook remains mixed: Analysts generally rate IOVA positively, with a “Moderate Buy” consensus and a $13.20 target price, but some coverage warns that the stock may be fully valued and vulnerable to a sell-the-news reaction.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report)'s share price gapped down before the market opened on Thursday. The stock had previously closed at $14.81, but opened at $10.70. Iovance Biotherapeutics shares last traded at $10.0730, with a volume of 17,767,226 shares.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients in the IOV-LUN-202 trial, consistent with earlier results. The KRAS wild-type subgroup posted a 43.3% response rate, versus 11.4% for KRAS-mutant disease, while a biomarker-enriched subgroup reached 59.1%. The data support a planned supplemental Biologics License Application for lifileucel in non-squamous mNSCLC in 2027. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: Iovance plans to begin enrollment in November 2026 for POSITILITY, a biomarker-enriched study with registrational intent, expanding its precision TIL strategy in lung cancer. Iovance Precision TIL Strategy
• Positive Sentiment: Unusually high options activity showed traders purchased 28,173 call contracts, approximately 70% above typical daily call volume, indicating increased speculative bullish interest.
• Positive Sentiment: Zacks upgraded IOVA from “hold” to “strong-buy,” and its earnings preview identifies factors that could support a beat in the upcoming report. Iovance Earnings Estimates Preview
• Neutral Sentiment: Additional lifileucel results showed a 50% response rate in refractory undifferentiated pleomorphic sarcoma and liposarcoma, broadening the potential opportunity for the company’s TIL platform. Lifileucel Sarcoma Results
• Negative Sentiment: Some coverage argues that IOVA may already be fully valued following recent melanoma and ESMO-related data, raising the risk of a “sell-the-news” reaction even as the clinical results remain promising. Iovance Valuation Analysis

Wall Street Analysts Forecast Growth

Several research analysts have commented on IOVA shares. Zacks Research raised Iovance Biotherapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday. Citizens Jmp upped their target price on Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a "market outperform" rating in a research report on Friday, August 7th. TD Cowen upped their target price on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday, August 24th. Citigroup reiterated an "outperform" rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. Finally, Mizuho raised their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an "outperform" rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $13.20.

Iovance Biotherapeutics Stock Performance

The company has a market capitalization of $4.34 billion, a PE ratio of -13.04 and a beta of 0.76. The company has a 50 day moving average price of $11.35 and a 200 day moving average price of $5.76.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The business had revenue of $99.31 million for the quarter, compared to analysts' expectations of $87.83 million. During the same quarter last year, the company posted ($0.33) earnings per share. The company's quarterly revenue was up 65.7% compared to the same quarter last year. On average, equities analysts forecast that Iovance Biotherapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Iovance Biotherapeutics during the 2nd quarter worth $153,744,000. Palo Alto Investors LP bought a new stake in Iovance Biotherapeutics during the second quarter worth approximately $22,032,229. Bank of America Corp DE bought a new stake in Iovance Biotherapeutics during the second quarter worth approximately $20,773,000. Dimensional Fund Advisors LP raised its holdings in Iovance Biotherapeutics by 71.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,645,702 shares of the biotechnology company's stock worth $9,282,000 after purchasing an additional 1,106,592 shares in the last quarter. Finally, Knott David M Jr acquired a new stake in Iovance Biotherapeutics in the first quarter worth approximately $5,616,000. 77.03% of the stock is owned by institutional investors and hedge funds.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc NASDAQ: IOVA is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.